Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non‐small‐cell lung cancer harboring EGFR mutations: Results from a real‐world study in South Korea

OBJECTIVES: The optimal sequence for the administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for treating non‐small cell lung cancer (NSCLC) is still unclear. This study aimed to evaluate the efficacy of sequential afatinib and osimertinib treatment in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Taeyun, Jang, Tae Won, Choi, Chang Min, Kim, Mi‐Hyun, Lee, Sung Yong, Park, Cheol‐Kyu, Chang, Yoon Soo, Lee, Kye Young, Kim, Seung Joon, Yang, Sei Hoon, Ryu, Jeong Seon, Lee, Jeong Eun, Lee, Shin Yup, Park, Chan Kwon, Lee, Sang Hoon, Jang, Seung Hun, Yoon, Seong Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419762/
https://www.ncbi.nlm.nih.gov/pubmed/34258882
http://dx.doi.org/10.1002/cam4.4127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419762/
https://www.ncbi.nlm.nih.gov/pubmed/34258882
http://dx.doi.org/10.1002/cam4.4127

Ejemplares similares